Thera-SAbDab

USTEKINUMAB

>   Structural Summary
TherapeuticUstekinumab
TargetIL12B
Heavy ChainEVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK
100% seqID Fv Structure3hmw [Fvs: HL], 3hmx [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedCentocor Inc, Janssen Biotech, Medarex
Conditions ApprovedCrohn's disease, Plaque psoriasis, Psoriatic arthritis
Conditions ActiveUlcerative colitis, Spondylarthritis, Systemic lupus erythematosus, Atopic dermatitis
Conditions DiscontinuedMultiple sclerosis, Palmoplantar pustulosis, Primary biliary cirrhosis, Rheumatoid arthritis, Sarcoidosis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]